“We see this investment as a way to participate in an exciting market with a differentiated and compelling technology,” said Dan Galles, General Partner at HLM. “In early clinicals, the Pathway Atherectomy System has shown great promise as an effective way to treat patients suffering from peripheral arterial disease.” He adds, “Physicians performing endovascular procedures continue to face clinical challenges. As a result, they look for easy-to-use, effective technologies. The Pathway Atherectomy System has the potential to address these challenges.”

Pathway CEO and President Tom Clement commented:” We are very pleased with this financing and the addition of HLM and Latterell as investors in Pathway. This investment round not only validates our team but also our technology and its potential in the marketplace.”

PAD is a serious disease affecting an estimated 14 million people in the U.S. PAD results when atherosclerotic obstructions cause narrowed or blocked arteries that reduce blood flow to the arms or legs. These blood flow restrictions can cause severe pain while performing relatively simple tasks. Over time, avoiding treatment could result in more severe complications, such as skin discoloration, infections and sores that will not heal and, in extreme cases, eventual amputation.

Pathway Medical Technologies, Inc., located in Redmond, Washington, was founded in 1998 to design, develop and manufacture innovative medical devices intended for the treatment of arterial disease. The company’s initial focus is on peripheral artery disease.